CN108096189A - A kind of elaioplast nanometer particle and its pharmaceutical composition and application - Google Patents
A kind of elaioplast nanometer particle and its pharmaceutical composition and application Download PDFInfo
- Publication number
- CN108096189A CN108096189A CN201611054679.8A CN201611054679A CN108096189A CN 108096189 A CN108096189 A CN 108096189A CN 201611054679 A CN201611054679 A CN 201611054679A CN 108096189 A CN108096189 A CN 108096189A
- Authority
- CN
- China
- Prior art keywords
- nanometer particle
- elaioplast nanometer
- pharmaceutical composition
- mixed liquor
- liposome vesicle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002245 particle Substances 0.000 title claims abstract description 41
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 17
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 23
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 20
- 239000002502 liposome Substances 0.000 claims abstract description 20
- 238000002360 preparation method Methods 0.000 claims abstract description 17
- 239000008187 granular material Substances 0.000 claims abstract description 12
- SQDAZGGFXASXDW-UHFFFAOYSA-N 5-bromo-2-(trifluoromethoxy)pyridine Chemical compound FC(F)(F)OC1=CC=C(Br)C=N1 SQDAZGGFXASXDW-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229920001287 Chondroitin sulfate Polymers 0.000 claims abstract description 10
- 235000012000 cholesterol Nutrition 0.000 claims abstract description 10
- 229940059329 chondroitin sulfate Drugs 0.000 claims abstract description 10
- 108010016290 deoxyribonucleoprotamine Proteins 0.000 claims abstract description 10
- 239000002105 nanoparticle Substances 0.000 claims abstract description 10
- MWRBNPKJOOWZPW-CLFAGFIQSA-N dioleoyl phosphatidylethanolamine Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(COP(O)(=O)OCCN)OC(=O)CCCCCCC\C=C/CCCCCCCC MWRBNPKJOOWZPW-CLFAGFIQSA-N 0.000 claims abstract description 7
- 125000001820 oxy group Chemical group [*:1]O[*:2] 0.000 claims abstract description 7
- 239000002202 Polyethylene glycol Substances 0.000 claims abstract description 4
- 150000001805 chlorine compounds Chemical class 0.000 claims abstract description 4
- 238000012986 modification Methods 0.000 claims abstract description 4
- 230000004048 modification Effects 0.000 claims abstract description 4
- 229920001223 polyethylene glycol Polymers 0.000 claims abstract description 4
- 239000003814 drug Substances 0.000 claims description 16
- 229940079593 drug Drugs 0.000 claims description 13
- 125000003729 nucleotide group Chemical group 0.000 claims description 13
- 108091033409 CRISPR Proteins 0.000 claims description 11
- 239000002773 nucleotide Substances 0.000 claims description 11
- 108020004707 nucleic acids Chemical class 0.000 claims description 10
- 102000039446 nucleic acids Human genes 0.000 claims description 10
- 150000007523 nucleic acids Chemical class 0.000 claims description 10
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 8
- 230000003068 static effect Effects 0.000 claims description 8
- 201000001441 melanoma Diseases 0.000 claims description 7
- OYINQIKIQCNQOX-UHFFFAOYSA-M 2-hydroxybutyl(trimethyl)azanium;chloride Chemical compound [Cl-].CCC(O)C[N+](C)(C)C OYINQIKIQCNQOX-UHFFFAOYSA-M 0.000 claims description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 239000000823 artificial membrane Substances 0.000 claims description 6
- 239000000203 mixture Substances 0.000 claims description 5
- 229920002477 rna polymer Polymers 0.000 claims description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 3
- 208000026310 Breast neoplasm Diseases 0.000 claims description 3
- 206010060862 Prostate cancer Diseases 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 230000008020 evaporation Effects 0.000 claims description 3
- 239000002953 phosphate buffered saline Substances 0.000 claims description 3
- 238000002390 rotary evaporation Methods 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 108020004414 DNA Proteins 0.000 claims description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 2
- JZNWSCPGTDBMEW-UHFFFAOYSA-N Glycerophosphorylethanolamin Natural products NCCOP(O)(=O)OCC(O)CO JZNWSCPGTDBMEW-UHFFFAOYSA-N 0.000 claims description 2
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 2
- -1 acyl phosphatidyl-ethanolamine Chemical class 0.000 claims description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 2
- 229940126534 drug product Drugs 0.000 claims description 2
- 239000008103 glucose Substances 0.000 claims description 2
- 238000010348 incorporation Methods 0.000 claims description 2
- 229940127554 medical product Drugs 0.000 claims description 2
- 229910052760 oxygen Inorganic materials 0.000 claims description 2
- 239000001301 oxygen Substances 0.000 claims description 2
- 229920001184 polypeptide Polymers 0.000 claims description 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims 2
- 229920002567 Chondroitin Polymers 0.000 claims 1
- 240000007594 Oryza sativa Species 0.000 claims 1
- 235000007164 Oryza sativa Nutrition 0.000 claims 1
- 235000013339 cereals Nutrition 0.000 claims 1
- DLGJWSVWTWEWBJ-HGGSSLSASA-N chondroitin Chemical compound CC(O)=N[C@@H]1[C@H](O)O[C@H](CO)[C@H](O)[C@@H]1OC1[C@H](O)[C@H](O)C=C(C(O)=O)O1 DLGJWSVWTWEWBJ-HGGSSLSASA-N 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 235000009566 rice Nutrition 0.000 claims 1
- 238000001890 transfection Methods 0.000 abstract description 10
- 230000001225 therapeutic effect Effects 0.000 abstract description 4
- LVNGJLRDBYCPGB-UHFFFAOYSA-N 1,2-distearoylphosphatidylethanolamine Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(COP([O-])(=O)OCC[NH3+])OC(=O)CCCCCCCCCCCCCCCCC LVNGJLRDBYCPGB-UHFFFAOYSA-N 0.000 abstract 1
- 238000012360 testing method Methods 0.000 description 10
- 239000013612 plasmid Substances 0.000 description 7
- 238000010354 CRISPR gene editing Methods 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 241000700605 Viruses Species 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000011017 operating method Methods 0.000 description 3
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- 108091027544 Subgenomic mRNA Proteins 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001415 gene therapy Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000012097 Lipofectamine 2000 Substances 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000011852 carbon nanoparticle Substances 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000010362 genome editing Methods 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 239000002122 magnetic nanoparticle Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Dispersion Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention provides a kind of elaioplast nanometer particle; the elaioplast nanometer particle is the nano particle wrapped up by liposome vesicle; the surface modification of the liposome vesicle has distearoylphosphatidylethanolamine polyethylene glycol; the nano particle is made of fat granule, chondroitin sulfate and nucleoprotamine; the liposome vesicle is made of dioleoylphosphatidylethanolamine, 2,3 two oily oxygroup hydroxypropyltrimonium chlorides and cholesterol.Preparation method the present invention also provides the elaioplast nanometer particle and its a kind of pharmaceutical composition including the elaioplast nanometer particle.Elaioplast nanometer particle provided by the invention has higher transfection as carrier, and pharmaceutical composition provided by the invention has preferable therapeutic effect for kinds of tumors.
Description
Technical field
The invention belongs to pharmaceutical technology fields.Specifically, the present invention provides a kind of elaioplast nanometer particle and its medicines
Compositions and application.
Background technology
At present, in the gene therapy of kinds of tumors, common carrier mainly has viral vectors and non-virus carrier.It is although sick
Poisonous carrier presents outstanding efficiency gene transfection, but they may trigger mutation and other carcinogenesises.Furthermore virus carries
The reuse of body may induce immune deficiency.And common non-virus carrier includes polymer, nano particle (magnetic nano particle
Son, gold nano grain, the carbon nano-particle with different surfaces modification) and commercial reagents (Lipofectamine2000,
Lipofectamine3000) etc., transfection efficiency is relatively low, it is impossible to good gene therapy effect is played to cancer.
CRISPR/Cas9 systems are a multi-functional gene editing platforms, are treating challenging disease (such as cancer
Disease) when have potential advantage.But since common Cas9 albumen size is larger, current common carrier is difficult it to be carried out efficiently
Delivering, limit its basic research and treatment application.
Therefore, a kind of suitable carrier is found efficiently to deliver the drug for treating tumour (such as CRISPR/Cas9 systems)
To tumor focus, just it is particularly important.
The content of the invention
Therefore, based on above-mentioned prior art the defects of, the object of the present invention is to provide a kind of elaioplast nanometer particle and its
Pharmaceutical composition and application.
For foregoing invention purpose, the present invention is achieved through the following technical solutions：
The present invention provides a kind of elaioplast nanometer particle (PLNP), wherein, the elaioplast nanometer particle is by liposome
The nano particle of vesica package, the surface modification of the liposome vesicle have distearoylphosphatidylethanolamine-polyethylene glycol
(DSPE-PEG), the nano particle is made of fat granule, chondroitin sulfate and nucleoprotamine, and the liposome vesicle is by dioleoyl
The oily oxygroup hydroxypropyltrimonium chloride (DOTAP) of phosphatidyl-ethanolamine (DOPE), 2,3- bis- and cholesterol composition.Preferably, root
According to foregoing elaioplast nanometer particle, wherein, fat granule, chondroitin sulfate and nucleoprotamine molar ratio in the nano particle are
0.1~5：0.1~8：0.1~10.Preferably 0.2~4：0.2~5：0.1~6.
It is highly preferred that according to foregoing elaioplast nanometer particle, wherein, the dioleoyl phospholipid acyl in the liposome vesicle
The oily oxygroup hydroxypropyltrimonium chloride of ethanolamine, 2,3- bis- and cholesterol molar ratio are 0.5~100：0.5~100：0.5~
100.Preferably 1~100：1~100：1~100.More preferably 1~20：1~20：1~20.
The present invention also provides a kind of preparation method of foregoing elaioplast nanometer particle, wherein, the described method includes：(1)
According to proportioning, the first mixed liquor of static acquisition after fat granule is mixed with chondroitin sulfate, (2) obtain step (1) according to proportioning
The first mixed liquor mixed with nucleoprotamine after the second mixed liquor of static acquisition, (3) according to proportioning, step (2) is obtained the
Two mixed liquors the 3rd mixed liquor of static acquisition after being mixed with liposome vesicle, (4) according to proportioning, step (3) is obtained the 3rd
Mixed liquor is mixed with DSPE-PEG obtains the elaioplast nanometer particle.Preferably, step (1), (2), the quiescent time of (3)
And/or the incorporation time of (4) is 15-30 minutes.Wherein, fat granule can be in water, PBS or grape with chondroitin sulfate in step (1)
It is mixed in sugar juice.Mixing temperature described in step (4) can be 55 DEG C.
Preferably, according to foregoing preparation method, wherein, the preparation method bag of the liposome vesicle in step (3)
It includes：(a) according to proportioning, dioleoylphosphatidylethanolamine, the oily oxygroup hydroxypropyltrimonium chlorides of 2,3- bis- and cholesterol are dissolved in
In the mixed liquor of chloroform and methanol；(b) rotary evaporation step (a) obtain the mixed liquor to only remain immobilized artificial membrane；(c) in step
(b) water, PBS or glucose are added in the immobilized artificial membrane obtained；(d) ultrasound is to forming the liposome vesicle.Preferably, walk
Suddenly the rotating evaporation temperature in (b) is 30-35 DEG C.
The preparation method of foregoing elaioplast nanometer particle specifically can be as shown in Figure 1.
The present invention also provides a kind of pharmaceutical composition, wherein, described pharmaceutical composition includes the drug for the treatment of tumour with before
The elaioplast nanometer particle stated.Wherein, the elaioplast nanometer particle can be as the carrier of the drug.
Preferably, according to foregoing pharmaceutical composition, wherein, the drug of the treatment tumour is selected from following one kind or more
Kind：Nucleotide, nucleotide derivative, nucleic acid, nucleic acid derivative, polypeptide and albumen.
It is highly preferred that according to foregoing pharmaceutical composition, wherein, it is described when the drug of the treatment tumour includes nucleic acid
The nucleotide sequence of nucleic acid such as SEQ ID NO：Any one shown in 1-3 or such as SEQ ID NO：Any one shown in 1-3
Nucleotide sequence is substituted, lacks or adds one or several nucleotide and the nucleotide sequence with identical function.Preferably,
The nucleic acid be selected from DNA, small interference ribonucleic acid (siRNA) and one kind in guiding ribonucleic acid (sgRNA) or
It is a variety of.Wherein, SEQ ID NO:1-3 is respectively designated as sgPLK-1a, sgPLK-1b and sgPLK-1c.
More preferably, according to foregoing pharmaceutical composition, wherein, it is described when the drug of the treatment tumour includes albumen
Albumen is Cas9.
In some embodiments, in described pharmaceutical composition, the drug of the treatment tumour is CRISPR/Cas9 systems
System.Wherein, in the CRISPR/Cas9 systems sgRNA nucleotide sequence such as SEQ ID NO：Any one shown in 1-3.
The present invention also provides foregoing elaioplast nanometer particle or foregoing pharmaceutical composition preparing for treating tumour
Drug or medical product in application.Preferably, the tumour is melanoma, prostate cancer or breast cancer.
Elaioplast nanometer particle provided by the invention has higher transfection, drug provided by the invention as carrier
Composition has preferable therapeutic effect for kinds of tumors.
Description of the drawings
Hereinafter, the embodiment that the present invention will be described in detail is carried out with reference to attached drawing, wherein：
Fig. 1 shows the preparation method of elaioplast nanometer particle provided by the invention；
Fig. 2 shows the nano particle prepared by embodiment 1；
Fig. 3~Fig. 5 shows in-vitro transfection of the elaioplast nanometer particle as carrier to tumour cell described in embodiment 1
Effect；
Fig. 6 shows the elaioplast nanometer particle and the effect of other treatment method treatment melanoma described in embodiment 1
Compare：The variation for being tumor weight within treatment time.
Specific embodiment
It is further illustrated the present invention below by specific embodiment, it should be understood, however, that, these embodiments are only
It is used for specifically describing in more detail, and is not to be construed as limiting the present invention in any form.
In following embodiment, in addition to the test material, condition and the operating method that particularly point out, used in embodiment
Many materials and operating method are well known in the art.Therefore, it will be apparent to those skilled in the art that within a context, if not special
Do not mentionlet alone bright, material therefor of the present invention and operating method are well known in the art.
The reagent and instrument used in following embodiment is as follows：
Reagent：Shanghai Sigma-Aldrich.
Fat granule：Only Shang Lide.
Embodiment 1：
The present embodiment is used for the preparation method for illustrating elaioplast nanometer particle provided by the invention.
Fat granule, chondroitin sulfate and nucleoprotamine molar ratio are 0.2：4：4.Dioleoylphosphatidylethanolamine, bis- oil of 2,3-
Oxygroup hydroxypropyltrimonium chloride and cholesterol molar ratio are 1：13：14.
The preparation method is specific as follows：
(1) according to proportioning, fat granule is mixed with chondroitin sulfate obtains the first mixed liquor, 15-30 minutes static,
(2) according to proportioning, the first mixed liquor that step (1) is obtained is mixed with nucleoprotamine obtains the second mixed liquor, quiet
Only 15-30 minutes,
(3) according to proportioning, the second mixed liquor that step (2) is obtained is mixed with liposome vesicle obtains the 3rd mixed liquor,
It is 15-30 minutes static,
(4) according to proportioning, by the 3rd mixed liquor that step (3) obtains and distearoylphosphatidylethanolamine-poly- second two
It is mixed at 55 DEG C of alcohol 15-30 minutes and obtains the elaioplast nanometer particle.
Wherein, the preparation method of the liposome vesicle in step (3) includes：
(a) according to proportioning, by dioleoylphosphatidylethanolamine, the oily oxygroup hydroxypropyltrimonium chlorides of 2,3- bis- and cholesterol
It is dissolved in the mixed liquor of chloroform and methanol,
(b) mixed liquor that rotary evaporation step (a) obtains is 30-35 DEG C to immobilized artificial membrane, rotating evaporation temperature is only remained
(c) water is added in the immobilized artificial membrane obtained in step (b),
(d) ultrasound is to forming the liposome vesicle.
The nano particle of preparation is as shown in Figure 2.
Embodiment 2~10
The present embodiment is used for the preparation method for illustrating elaioplast nanometer particle provided by the invention.
The elaioplast nanometer particle is prepared using preparation method described in embodiment 1.
Wherein, fat granule, chondroitin sulfate and nucleoprotamine molar ratio and the oily oxygen of dioleoylphosphatidylethanolamine, 2,3- bis-
Base hydroxypropyltrimonium chloride and cholesterol molar ratio such as following table：
Test example 1：
This test example is used for in-vitro transfection effect of the elaioplast nanometer particle to other tumour cells for illustrating invention offer.
Elaioplast nanometer particle (PLNP) prepared by embodiment 2 is chosen as carrier, respectively mediation comprising sgPLK-1a,
Plasmid transfection melanoma cells, prostate gland cancer cell and the breast cancer cell subjects difference of sgPLK-1b and sgPLK-1c
It is named as PLNP/DNAa, PLNP/DNAb and PLNP/DNAc.Lipo2000 is selected as control object.
Specific experiment method is as follows：
The preparation method synthesis elaioplast nanometer particle described in embodiment 2.
The plasmid of sgPLK-1a, the plasmid of sgPLK-1 and the plasmid of sgPLK-1c is respectively adopted in experiment.1 μ of plasmid concentration
G/mL, when transfection 3 is small in incubator.
Result of the test such as Fig. 3~Fig. 5, from result of the test as it can be seen that for not homotactic gene, method provided by the present invention
Preferable transfection can be reached.
Test example 2：
This test example is used for therapeutic effect of the elaioplast nanometer particle to treatment melanoma for illustrating invention offer.It chooses
Elaioplast nanometer particle (PLNP) prepared by embodiment 3 chooses Lipo2000 as control vector, is situated between respectively as test carrier
Plasmid (PLNP/DNA-a, Lipo2000/DNA-a) the transfection melanoma comprising sgPLK-1a is led, chooses physiological saline
(Saline) and the plasmid comprising sgPLK-1a (DNA-a) is used as blank control.
Specific experiment method is as follows：
The preparation method synthesis elaioplast nanometer particle described in embodiment 3.
Experiment is implanted into after melanoma cells 1-2 weeks, using magnetic nude mice (6-8 weeks age, weight 18-20g) using swollen
The mode of knurl in-situ injection.Experimental group is divided into 8 groups, every group four.Administration 16 days, is administered once for every two days, every per injection
10μg。
Result of the test such as Fig. 6, from result of the test as it can be seen that method provided by the present invention can reach preferable transfection,
The therapeutic effect to tumour can preferably be played.The weight of tumour compared with the control group, there is apparent reduction.
Although here, a degree of description has been carried out to the present invention, it will be apparent that, do not depart from the present invention spirit and
Under conditions of scope, one of ordinary skill in the art can carry out the appropriate variation of each condition.It is understood that the present invention is unlimited
Summarize in the embodiment and specific example, right are attributed to the scope of claim, and including each factor etc.
With replacement.
Claims (10)
1. a kind of elaioplast nanometer particle, which is characterized in that the elaioplast nanometer particle is receiving by liposome vesicle package
Rice grain, the surface modification of the liposome vesicle have distearoylphosphatidylethanolamine-polyethylene glycol, the nano particle
It is made of fat granule, chondroitin sulfate and nucleoprotamine, the liposome vesicle is by dioleoylphosphatidylethanolamine, the oily oxygen of 2,3- bis-
Base hydroxypropyltrimonium chloride and cholesterol composition.
2. elaioplast nanometer particle according to claim 1, which is characterized in that fat granule, sulfuric acid in the nano particle
Chondroitin and nucleoprotamine molar ratio are 0.1~5：0.1~8：0.1~10, it is preferably 0.2~4：0.2~5：0.1~6.
3. elaioplast nanometer particle according to claim 1 or 2, which is characterized in that two oil in the liposome vesicle
The oily oxygroup hydroxypropyltrimonium chloride of acyl phosphatidyl-ethanolamine, 2,3- bis- and cholesterol molar ratio are 0.5~100：05~100：
0.5~100, it is preferably 1~100：1~100：1~100, more preferably 1~20：1~20：1~20.
4. the preparation method of the elaioplast nanometer particle any one of a kind of claims 1 to 3, which is characterized in that described
Method includes：
(1) according to proportioning, the first mixed liquor of static acquisition after fat granule is mixed with chondroitin sulfate,
(2) according to proportioning, the second mixed liquor of static acquisition after the first mixed liquor that step (1) obtains is mixed with nucleoprotamine,
(3) it is static after the second mixed liquor that step (2) obtains is mixed with liposome vesicle to obtain the 3rd mixing according to proportioning
Liquid,
(4) according to proportioning, the 3rd mixed liquor that step (3) obtains is mixed with distearoylphosphatidylethanolamine-polyethylene glycol
It closes and obtains the elaioplast nanometer particle；
Preferably, step (1), (2), the incorporation time of the quiescent time of (3) and/or (4) are 15-30 minutes.
5. preparation method according to claim 4, which is characterized in that the preparation of the liposome vesicle in step (3)
Method includes：
(a) according to proportioning, dioleoylphosphatidylethanolamine, the oily oxygroup hydroxypropyltrimonium chlorides of 2,3- bis- and cholesterol are dissolved in
In the mixed liquor of chloroform and methanol,
(b) rotary evaporation step (a) obtain the mixed liquor to only remain immobilized artificial membrane,
(c) water, PBS or glucose are added in the immobilized artificial membrane obtained in step (b),
(d) ultrasound is to forming the liposome vesicle；
Preferably, the rotating evaporation temperature in step (b) is 30-35 DEG C.
6. a kind of pharmaceutical composition, which is characterized in that described pharmaceutical composition include treatment tumour drug and claim 1 to
Elaioplast nanometer particle described in 3 any one.
7. pharmaceutical composition according to claim 6, which is characterized in that the drug of the treatment tumour is selected from following one
Kind is a variety of：Nucleotide, nucleotide derivative, nucleic acid, nucleic acid derivative, polypeptide and albumen.
8. the pharmaceutical composition according to claim 6 or 7, which is characterized in that the drug of the treatment tumour includes nucleic acid
When, the nucleotide sequence such as SEQ ID NO of the nucleic acid：Any one shown in 1-3 or such as SEQ ID NO：Appointing shown in 1-3
A kind of nucleotide sequence of anticipating is substituted, lacks or adds one or several nucleotide and the nucleotide sequence with identical function；
Preferably, the nucleic acid is selected from DNA, small interference ribonucleic acid and the one or more being oriented in ribonucleic acid.
9. the pharmaceutical composition according to any one of claim 6 to 8, which is characterized in that the drug of the treatment tumour
During including albumen, the albumen is Cas9.
10. the medicine any one of elaioplast nanometer particle or claim 6 to 9 any one of claims 1 to 3
Application of the compositions in the drug or medical product for treating tumour is prepared；Preferably, the tumour for melanoma,
Prostate cancer or breast cancer.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611054679.8A CN108096189A (en) | 2016-11-25 | 2016-11-25 | A kind of elaioplast nanometer particle and its pharmaceutical composition and application |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611054679.8A CN108096189A (en) | 2016-11-25 | 2016-11-25 | A kind of elaioplast nanometer particle and its pharmaceutical composition and application |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN108096189A true CN108096189A (en) | 2018-06-01 |
Family
ID=62205196
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201611054679.8A Pending CN108096189A (en) | 2016-11-25 | 2016-11-25 | A kind of elaioplast nanometer particle and its pharmaceutical composition and application |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108096189A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110755382A (en) * | 2019-11-15 | 2020-02-07 | 中国医学科学院医药生物技术研究所 | Targeted nucleic acid medicament and preparation method and application thereof |
| CN114867472A (en) * | 2019-12-23 | 2022-08-05 | 巴斯克大学 | Gold lipid nanoparticles for gene therapy |
| CN117025592A (en) * | 2023-07-05 | 2023-11-10 | 北京大学 | Small interfering RNA targeting JFK and application thereof |
| CN117695410A (en) * | 2024-02-06 | 2024-03-15 | 中国人民解放军军事科学院军事医学研究院 | CRISPR/Cas9 nano antibacterial agent and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002034236A2 (en) * | 2000-10-25 | 2002-05-02 | The University Of British Columbia | Lipid formulations for target delivery |
| CN103194489A (en) * | 2013-03-26 | 2013-07-10 | 中国科学院过程工程研究所 | Novel cationic liposome nucleic acid pharmaceutical preparation as well as preparation method and application thereof |
| CN103550783A (en) * | 2013-04-27 | 2014-02-05 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Nucleic acid drug targeting delivery system and preparation method thereof |
-
2016
- 2016-11-25 CN CN201611054679.8A patent/CN108096189A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002034236A2 (en) * | 2000-10-25 | 2002-05-02 | The University Of British Columbia | Lipid formulations for target delivery |
| CN103194489A (en) * | 2013-03-26 | 2013-07-10 | 中国科学院过程工程研究所 | Novel cationic liposome nucleic acid pharmaceutical preparation as well as preparation method and application thereof |
| CN103550783A (en) * | 2013-04-27 | 2014-02-05 | 中国人民解放军军事医学科学院放射与辐射医学研究所 | Nucleic acid drug targeting delivery system and preparation method thereof |
Non-Patent Citations (3)
| Title |
|---|
| MARIA LAURA IMMORDINO 等: "Stealth liposomes: review of the basic science,rationale, and clinical applications, existing and potential", 《INTERNATIONAL JOURNAL OF NANOMEDICINE》 * |
| MING WANG等: "Efficient delivery of genome-editing proteins using bioreducible lipid nanoparticles", 《PNAS》 * |
| TING YANG 等: "Tumor-targeted delivery of siRNA by surface-modified LPC nanoparticles", 《JOURNAL OF CHINESE PHARMACEUTICAL SCIENCES》 * |
Cited By (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110755382A (en) * | 2019-11-15 | 2020-02-07 | 中国医学科学院医药生物技术研究所 | Targeted nucleic acid medicament and preparation method and application thereof |
| CN110755382B (en) * | 2019-11-15 | 2022-07-12 | 中国医学科学院医药生物技术研究所 | Targeted nucleic acid medicament and preparation method and application thereof |
| CN114867472A (en) * | 2019-12-23 | 2022-08-05 | 巴斯克大学 | Gold lipid nanoparticles for gene therapy |
| CN114867472B (en) * | 2019-12-23 | 2024-04-19 | 巴斯克大学 | Gold lipid nanoparticles for gene therapy |
| CN117025592A (en) * | 2023-07-05 | 2023-11-10 | 北京大学 | Small interfering RNA targeting JFK and application thereof |
| CN117025592B (en) * | 2023-07-05 | 2024-05-14 | 北京大学 | Small interfering RNA targeting JFK and application thereof |
| CN117695410A (en) * | 2024-02-06 | 2024-03-15 | 中国人民解放军军事科学院军事医学研究院 | CRISPR/Cas9 nano antibacterial agent and preparation method thereof |
| CN117695410B (en) * | 2024-02-06 | 2024-05-03 | 中国人民解放军军事科学院军事医学研究院 | CRISPR/Cas9 nano antibacterial agent and preparation method thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Nsairat et al. | Liposomes: Structure, composition, types, and clinical applications | |
| Zukancic et al. | The importance of poly (Ethylene glycol) and lipid structure in targeted gene delivery to lymph nodes by lipid nanoparticles | |
| Yan et al. | Harnessing lipid nanoparticles for efficient CRISPR delivery | |
| Kim et al. | A promising biocompatible platform: lipid-based and bio-inspired smart drug delivery systems for cancer therapy | |
| CN107980004A (en) | Purposes for the excretion body for the treatment of disease | |
| Mashima et al. | Lipid nanoparticles: a novel gene delivery technique for clinical application | |
| CN1177291A (en) | Stable lipid-comprising drug delivery complexes and method for producing same | |
| CN107022516A (en) | A kind of method that surface modification part is steeped in cell microcapsule | |
| CN108096189A (en) | A kind of elaioplast nanometer particle and its pharmaceutical composition and application | |
| CN108143718B (en) | Anti-tumor nano gene medicine and preparation method and application thereof | |
| CN108498460A (en) | Gold nanoclusters-liposome composite particles and its preparation method and application | |
| Kurimoto et al. | PEG-OligoRNA hybridization of mRNA for developing sterically stable lipid nanoparticles toward in vivo administration | |
| CN108498461A (en) | Gold nano-liposome composite nanometer particle and its pharmaceutical composition and application | |
| Moshed et al. | The Application of nanotechnology in medical sciences: New horizon of treatment | |
| CN111450061A (en) | Hybrid mesenchymal stem cell exosome drug delivery system and preparation method and application thereof | |
| Li et al. | Polymeric DNA hydrogels and their applications in drug delivery for cancer therapy | |
| Sun et al. | PAMAM-functionalized cellulose nanocrystals with needle-like morphology for effective cancer treatment | |
| Fumoto et al. | Understanding in vivo fate of nucleic acid and gene medicines for the rational design of drugs | |
| CN108904468A (en) | A method of building targets extracellular vesica | |
| Chis et al. | Dendrimers as non-viral vectors in gene-directed enzyme prodrug therapy | |
| Rahimi et al. | BSA-PEI nanoparticle mediated efficient delivery of CRISPR/Cas9 into MDA-MB-231 Cells | |
| CN109111575B (en) | Preparation method and application of metal-organic framework nano-particles | |
| Della Pelle et al. | Nucleic acid delivery with red-blood-cell-based carriers | |
| CN102784398B (en) | Composition comprising endostatin adopted as delivery system and chemically-synthesized RNA interference molecule, and application thereof | |
| CN1608675A (en) | Medicine-carrying nanometer polymer particle and its prepn and use |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180601 |
|
| RJ01 | Rejection of invention patent application after publication |